FRET Biosensors for High-Throughput Drug Specificity Screening
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current drug development methods are hindered by the challenge of predicting and identifying off-target effects of drugs, which can lead to severe side effects such as heart attacks and strokes, due to the lack of sensitive and cost-effective high-throughput assays for evaluating the efficacy and specificity of therapeutic compounds.
Innovation Solution
The development of FRET-based protein biosensor constructs that are inserted into mammalian cells to monitor changes in fluorescence intensity in response to candidate drugs, allowing for the identification of pathway-specific biosensors and the evaluation of drug efficacy and specificity through ratiometric fluorescence measurements.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional drug screening methods are used, then drug development can proceed with standard assays, but off-target effects cannot be reliably predicted leading to severe side effects
Solution Approach 1:
The patent segments the complex task of drug screening by dividing it into multiple specialized biosensors, each targeting specific biochemical pathways. This allows reliable detection of off-target effects across different pathways while maintaining manageable individual sensor complexity.
Solution Approach 2:
The patent creates a universal biosensor platform with a common backbone structure that can detect multiple different biochemical pathways by swapping sensing domains. This multi-functional approach enables comprehensive off-target effect prediction without requiring entirely separate assay systems for each pathway.
2Measurement precision
If sensitive assays are developed to detect off-target effects, then prediction accuracy improves, but cost and complexity increase
Solution Approach 1:
The patent applies local quality by concentrating detection sensitivity at the sensing domain level while keeping the backbone structure standardized and relatively simple. Each biosensor has high local sensitivity for its specific target, but the overall system complexity is controlled through modular design.
Solution Approach 2:
The patent uses a copied backbone structure across all biosensors in the panel, which simplifies the overall system while maintaining high detection precision through specialized sensing domains. This copying approach reduces redundancy and controls complexity.
3Productivity
If high throughput screening is implemented, then drug evaluation efficiency increases, but resource requirements and cost increase
Solution Approach 1:
The patent merges multiple pathway detection capabilities into a single integrated biosensor panel that can be used simultaneously for screening multiple drugs across different pathways. This combining approach achieves high throughput while reducing total resource consumption compared to running separate assays for each pathway.
Solution Approach 2:
The universal biosensor platform enables a single assay system to evaluate drugs across multiple biochemical pathways, increasing productivity without proportionally increasing resources. The same backbone and detection methodology serve multiple functions across different pathway assessments.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables rapid and efficient assessment of drug efficacy and specificity, reducing the risk of side effects by providing a sensitive and cost-effective method for high-throughput drug screening and discovery.
Implementation Method 1
the biosensor translates activation or repression of a biochemical pathway into dynamically changing ratiometric fluorescence intensity between two fluorescent domains in each biosensor, which can be measured quickly and efficiently with a fluorescence detector. The ratiometric fluorescence intensity between two fluorescent domains in each biosensor can be the ratio of either direct fluorescence from each of the two fluorescent domains in each biosensor, or the forster resonance energy transfer ratio (FRET ratio) between each of the two fluorescent domains in each biosensor.
Data Source
AI summary
Provided are FRET-based biosensor constructs, and multiplexed platforms or arrays of these biosensor constructs useful for screening candidate drug molecules for efficacy and/or specificity of drug activity. Optionally the biosensor constructs may be located on an inner membrane within a cell or engineered to be located on the cell's surface. The cells or cell lines displaying the biosensors on a cell surface may be arranged as an array of cells for high throughput evaluation of the efficacy and/or specificity of drug candidates, such as a library of candidate drug compounds.